Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2022 08:00 ET | Source: Longeveron

Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer

MIAMI, April 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
March 31, 2022 08:00 ET | Source: Longeveron

Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association

Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer’s PatientsPhase 2 Trial Recently Launched With First Patient...
March 24, 2022 08:00 ET | Source: Longeveron

Longeveron Presents at Second Euro-Geroscience Conference

MIAMI, March 24, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
March 15, 2022 08:00 ET | Source: Longeveron

Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference

MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
March 11, 2022 08:00 ET | Source: Longeveron

Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer’s Disease (Phase 2a), and Covid-related Acute Respiratory...
March 07, 2022 08:00 ET | Source: Longeveron

Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022

MIAMI, March 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
March 02, 2022 08:00 ET | Source: Longeveron

Longeveron to Present at Q1 Virtual Investor Summit Conference

MIAMI, March 02, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
February 17, 2022 08:00 ET | Source: Longeveron

Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
January 25, 2022 08:00 ET | Source: Longeveron

Longeveron to Participate in Phacilitate Advanced Therapies Week

MIAMI, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
January 12, 2022 08:00 ET | Source: Longeveron

Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic...